BioPharma Dive June 7, 2024
The FDA approved Geron’s drug Rytelo for myelodysplastic syndromes, while the agency’s commissioners spoke on some of biotech’s buzziest topics at a Wednesday panel.
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San Diego, as well as notes on Geron, AbbVie and Deerfield Management.
Food and Drug Administration Commissioner Robert Califf, speaking on a Wednesday panel, told BIO president John Crowley that he did not want to see the pharmaceutical industry “completely dependent” on China, an issue that’s been in focus as Congress considers legislation targeting certain Chinese companies. “There could be a catastrophic thing like an earthquake or a geopolitical war, so you want to have a distributed...
Today's Sponsors
Today's Sponsor